nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—CYP3A4—Rivastigmine—Alzheimer's disease	0.0616	0.432	CbGbCtD
Dabrafenib—CYP3A4—Donepezil—Alzheimer's disease	0.0492	0.345	CbGbCtD
Dabrafenib—CYP3A4—Galantamine—Alzheimer's disease	0.0317	0.223	CbGbCtD
Dabrafenib—SLC22A8—choroid plexus—Alzheimer's disease	0.0294	0.249	CbGeAlD
Dabrafenib—LIMK1—telencephalon—Alzheimer's disease	0.00866	0.0733	CbGeAlD
Dabrafenib—NEK11—cerebellum—Alzheimer's disease	0.00672	0.0569	CbGeAlD
Dabrafenib—NEK11—brain—Alzheimer's disease	0.00546	0.0462	CbGeAlD
Dabrafenib—SIK1—forebrain—Alzheimer's disease	0.00487	0.0412	CbGeAlD
Dabrafenib—LIMK1—cerebellum—Alzheimer's disease	0.00481	0.0407	CbGeAlD
Dabrafenib—SIK1—telencephalon—Alzheimer's disease	0.00448	0.0379	CbGeAlD
Dabrafenib—RAF1—embryo—Alzheimer's disease	0.00438	0.0371	CbGeAlD
Dabrafenib—LIMK1—brain—Alzheimer's disease	0.00391	0.0331	CbGeAlD
Dabrafenib—RAF1—forebrain—Alzheimer's disease	0.00387	0.0328	CbGeAlD
Dabrafenib—RAF1—telencephalon—Alzheimer's disease	0.00356	0.0302	CbGeAlD
Dabrafenib—BRAF—cerebellum—Alzheimer's disease	0.00297	0.0251	CbGeAlD
Dabrafenib—SIK1—nervous system—Alzheimer's disease	0.00264	0.0224	CbGeAlD
Dabrafenib—SIK1—central nervous system—Alzheimer's disease	0.00254	0.0215	CbGeAlD
Dabrafenib—SIK1—cerebellum—Alzheimer's disease	0.00249	0.021	CbGeAlD
Dabrafenib—BRAF—brain—Alzheimer's disease	0.00241	0.0204	CbGeAlD
Dabrafenib—RAF1—nervous system—Alzheimer's disease	0.0021	0.0178	CbGeAlD
Dabrafenib—RAF1—central nervous system—Alzheimer's disease	0.00203	0.0171	CbGeAlD
Dabrafenib—SIK1—brain—Alzheimer's disease	0.00202	0.0171	CbGeAlD
Dabrafenib—RAF1—cerebellum—Alzheimer's disease	0.00198	0.0168	CbGeAlD
Dabrafenib—RAF1—brain—Alzheimer's disease	0.00161	0.0136	CbGeAlD
Dabrafenib—SLC22A6—brain—Alzheimer's disease	0.00156	0.0132	CbGeAlD
Dabrafenib—Cardiac failure congestive—Memantine—Alzheimer's disease	0.00154	0.00377	CcSEcCtD
Dabrafenib—Renal failure acute—Memantine—Alzheimer's disease	0.00152	0.00371	CcSEcCtD
Dabrafenib—Renal failure—Galantamine—Alzheimer's disease	0.00151	0.00368	CcSEcCtD
Dabrafenib—ABCB1—blood vessel—Alzheimer's disease	0.0015	0.0127	CbGeAlD
Dabrafenib—Urinary tract infection—Galantamine—Alzheimer's disease	0.00149	0.00364	CcSEcCtD
Dabrafenib—Renal failure acute—Rivastigmine—Alzheimer's disease	0.00148	0.00363	CcSEcCtD
Dabrafenib—ABCG2—telencephalon—Alzheimer's disease	0.00147	0.0125	CbGeAlD
Dabrafenib—Dermatitis bullous—Memantine—Alzheimer's disease	0.00146	0.00358	CcSEcCtD
Dabrafenib—Haematuria—Galantamine—Alzheimer's disease	0.00146	0.00357	CcSEcCtD
Dabrafenib—Epistaxis—Galantamine—Alzheimer's disease	0.00145	0.00353	CcSEcCtD
Dabrafenib—Blood creatinine increased—Donepezil—Alzheimer's disease	0.00144	0.00353	CcSEcCtD
Dabrafenib—Dehydration—Donepezil—Alzheimer's disease	0.00143	0.0035	CcSEcCtD
Dabrafenib—Dermatitis bullous—Rivastigmine—Alzheimer's disease	0.00143	0.0035	CcSEcCtD
Dabrafenib—Dry skin—Donepezil—Alzheimer's disease	0.00141	0.00345	CcSEcCtD
Dabrafenib—Abdominal pain upper—Donepezil—Alzheimer's disease	0.00141	0.00344	CcSEcCtD
Dabrafenib—Hyponatraemia—Memantine—Alzheimer's disease	0.00141	0.00344	CcSEcCtD
Dabrafenib—Hypokalaemia—Donepezil—Alzheimer's disease	0.0014	0.00343	CcSEcCtD
Dabrafenib—Pain in extremity—Memantine—Alzheimer's disease	0.0014	0.00342	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Donepezil—Alzheimer's disease	0.00139	0.00339	CcSEcCtD
Dabrafenib—Haemoglobin—Galantamine—Alzheimer's disease	0.00138	0.00338	CcSEcCtD
Dabrafenib—Nasopharyngitis—Donepezil—Alzheimer's disease	0.00138	0.00337	CcSEcCtD
Dabrafenib—Haemorrhage—Galantamine—Alzheimer's disease	0.00138	0.00336	CcSEcCtD
Dabrafenib—Hyponatraemia—Rivastigmine—Alzheimer's disease	0.00138	0.00336	CcSEcCtD
Dabrafenib—Pain in extremity—Rivastigmine—Alzheimer's disease	0.00137	0.00335	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Donepezil—Alzheimer's disease	0.00136	0.00332	CcSEcCtD
Dabrafenib—Urinary tract disorder—Galantamine—Alzheimer's disease	0.00136	0.00332	CcSEcCtD
Dabrafenib—Oedema peripheral—Galantamine—Alzheimer's disease	0.00136	0.00331	CcSEcCtD
Dabrafenib—Connective tissue disorder—Galantamine—Alzheimer's disease	0.00135	0.00331	CcSEcCtD
Dabrafenib—Urethral disorder—Galantamine—Alzheimer's disease	0.00135	0.0033	CcSEcCtD
Dabrafenib—Blood creatinine increased—Memantine—Alzheimer's disease	0.00131	0.00321	CcSEcCtD
Dabrafenib—Pancreatitis—Donepezil—Alzheimer's disease	0.00131	0.00319	CcSEcCtD
Dabrafenib—Dehydration—Memantine—Alzheimer's disease	0.0013	0.00318	CcSEcCtD
Dabrafenib—Eye disorder—Galantamine—Alzheimer's disease	0.00129	0.00314	CcSEcCtD
Dabrafenib—Dry skin—Memantine—Alzheimer's disease	0.00128	0.00314	CcSEcCtD
Dabrafenib—Abdominal discomfort—Donepezil—Alzheimer's disease	0.00128	0.00312	CcSEcCtD
Dabrafenib—Hypokalaemia—Memantine—Alzheimer's disease	0.00127	0.00311	CcSEcCtD
Dabrafenib—Dehydration—Rivastigmine—Alzheimer's disease	0.00127	0.00311	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Memantine—Alzheimer's disease	0.00126	0.00308	CcSEcCtD
Dabrafenib—Dry skin—Rivastigmine—Alzheimer's disease	0.00126	0.00307	CcSEcCtD
Dabrafenib—Nasopharyngitis—Memantine—Alzheimer's disease	0.00125	0.00306	CcSEcCtD
Dabrafenib—Abdominal pain upper—Rivastigmine—Alzheimer's disease	0.00125	0.00306	CcSEcCtD
Dabrafenib—Angiopathy—Galantamine—Alzheimer's disease	0.00125	0.00305	CcSEcCtD
Dabrafenib—Hypokalaemia—Rivastigmine—Alzheimer's disease	0.00125	0.00305	CcSEcCtD
Dabrafenib—Immune system disorder—Galantamine—Alzheimer's disease	0.00124	0.00304	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Memantine—Alzheimer's disease	0.00123	0.00302	CcSEcCtD
Dabrafenib—Arrhythmia—Galantamine—Alzheimer's disease	0.00123	0.00301	CcSEcCtD
Dabrafenib—Nasopharyngitis—Rivastigmine—Alzheimer's disease	0.00122	0.00299	CcSEcCtD
Dabrafenib—SLC22A8—nervous system—Alzheimer's disease	0.00122	0.0103	CbGeAlD
Dabrafenib—Mental disorder—Galantamine—Alzheimer's disease	0.00121	0.00295	CcSEcCtD
Dabrafenib—Hyperglycaemia—Donepezil—Alzheimer's disease	0.0012	0.00294	CcSEcCtD
Dabrafenib—Malnutrition—Galantamine—Alzheimer's disease	0.0012	0.00293	CcSEcCtD
Dabrafenib—Infestation NOS—Donepezil—Alzheimer's disease	0.00119	0.0029	CcSEcCtD
Dabrafenib—Infestation—Donepezil—Alzheimer's disease	0.00119	0.0029	CcSEcCtD
Dabrafenib—Pancreatitis—Memantine—Alzheimer's disease	0.00119	0.0029	CcSEcCtD
Dabrafenib—SLC22A8—central nervous system—Alzheimer's disease	0.00118	0.00996	CbGeAlD
Dabrafenib—Renal failure—Donepezil—Alzheimer's disease	0.00117	0.00285	CcSEcCtD
Dabrafenib—Pancreatitis—Rivastigmine—Alzheimer's disease	0.00116	0.00284	CcSEcCtD
Dabrafenib—Back pain—Galantamine—Alzheimer's disease	0.00116	0.00283	CcSEcCtD
Dabrafenib—Urinary tract infection—Donepezil—Alzheimer's disease	0.00115	0.00282	CcSEcCtD
Dabrafenib—Muscle spasms—Galantamine—Alzheimer's disease	0.00115	0.00282	CcSEcCtD
Dabrafenib—Haematuria—Donepezil—Alzheimer's disease	0.00113	0.00277	CcSEcCtD
Dabrafenib—Neutropenia—Memantine—Alzheimer's disease	0.00113	0.00277	CcSEcCtD
Dabrafenib—Vision blurred—Galantamine—Alzheimer's disease	0.00113	0.00276	CcSEcCtD
Dabrafenib—Epistaxis—Donepezil—Alzheimer's disease	0.00112	0.00274	CcSEcCtD
Dabrafenib—Anaemia—Galantamine—Alzheimer's disease	0.00111	0.00271	CcSEcCtD
Dabrafenib—Hyperglycaemia—Memantine—Alzheimer's disease	0.00109	0.00267	CcSEcCtD
Dabrafenib—Infestation—Memantine—Alzheimer's disease	0.00108	0.00264	CcSEcCtD
Dabrafenib—Infestation NOS—Memantine—Alzheimer's disease	0.00108	0.00264	CcSEcCtD
Dabrafenib—Haemoglobin—Donepezil—Alzheimer's disease	0.00107	0.00262	CcSEcCtD
Dabrafenib—Hyperglycaemia—Rivastigmine—Alzheimer's disease	0.00107	0.00261	CcSEcCtD
Dabrafenib—Haemorrhage—Donepezil—Alzheimer's disease	0.00107	0.00261	CcSEcCtD
Dabrafenib—Renal failure—Memantine—Alzheimer's disease	0.00106	0.00259	CcSEcCtD
Dabrafenib—Infestation NOS—Rivastigmine—Alzheimer's disease	0.00106	0.00258	CcSEcCtD
Dabrafenib—Infestation—Rivastigmine—Alzheimer's disease	0.00106	0.00258	CcSEcCtD
Dabrafenib—Urinary tract disorder—Donepezil—Alzheimer's disease	0.00105	0.00257	CcSEcCtD
Dabrafenib—Oedema peripheral—Donepezil—Alzheimer's disease	0.00105	0.00257	CcSEcCtD
Dabrafenib—Urinary tract infection—Memantine—Alzheimer's disease	0.00105	0.00256	CcSEcCtD
Dabrafenib—Urethral disorder—Donepezil—Alzheimer's disease	0.00105	0.00256	CcSEcCtD
Dabrafenib—Cough—Galantamine—Alzheimer's disease	0.00105	0.00256	CcSEcCtD
Dabrafenib—Renal failure—Rivastigmine—Alzheimer's disease	0.00104	0.00254	CcSEcCtD
Dabrafenib—Hypertension—Galantamine—Alzheimer's disease	0.00103	0.00253	CcSEcCtD
Dabrafenib—Haematuria—Memantine—Alzheimer's disease	0.00103	0.00251	CcSEcCtD
Dabrafenib—Urinary tract infection—Rivastigmine—Alzheimer's disease	0.00103	0.00251	CcSEcCtD
Dabrafenib—Myalgia—Galantamine—Alzheimer's disease	0.00102	0.00249	CcSEcCtD
Dabrafenib—Arthralgia—Galantamine—Alzheimer's disease	0.00102	0.00249	CcSEcCtD
Dabrafenib—Epistaxis—Memantine—Alzheimer's disease	0.00102	0.00249	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.00101	0.00248	CcSEcCtD
Dabrafenib—Haematuria—Rivastigmine—Alzheimer's disease	0.00101	0.00246	CcSEcCtD
Dabrafenib—Dry mouth—Galantamine—Alzheimer's disease	0.000998	0.00244	CcSEcCtD
Dabrafenib—Epistaxis—Rivastigmine—Alzheimer's disease	0.000996	0.00243	CcSEcCtD
Dabrafenib—Haemoglobin—Memantine—Alzheimer's disease	0.000973	0.00238	CcSEcCtD
Dabrafenib—Haemorrhage—Memantine—Alzheimer's disease	0.000969	0.00237	CcSEcCtD
Dabrafenib—Nervous system disorder—Galantamine—Alzheimer's disease	0.000959	0.00234	CcSEcCtD
Dabrafenib—Thrombocytopenia—Galantamine—Alzheimer's disease	0.000957	0.00234	CcSEcCtD
Dabrafenib—Chills—Donepezil—Alzheimer's disease	0.000957	0.00234	CcSEcCtD
Dabrafenib—Urinary tract disorder—Memantine—Alzheimer's disease	0.000956	0.00234	CcSEcCtD
Dabrafenib—Oedema peripheral—Memantine—Alzheimer's disease	0.000954	0.00233	CcSEcCtD
Dabrafenib—Arrhythmia—Donepezil—Alzheimer's disease	0.000953	0.00233	CcSEcCtD
Dabrafenib—Haemoglobin—Rivastigmine—Alzheimer's disease	0.000952	0.00233	CcSEcCtD
Dabrafenib—Connective tissue disorder—Memantine—Alzheimer's disease	0.000952	0.00233	CcSEcCtD
Dabrafenib—Skin disorder—Galantamine—Alzheimer's disease	0.00095	0.00232	CcSEcCtD
Dabrafenib—Urethral disorder—Memantine—Alzheimer's disease	0.000949	0.00232	CcSEcCtD
Dabrafenib—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000947	0.00232	CcSEcCtD
Dabrafenib—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000945	0.00231	CcSEcCtD
Dabrafenib—Alopecia—Donepezil—Alzheimer's disease	0.000943	0.0023	CcSEcCtD
Dabrafenib—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000936	0.00229	CcSEcCtD
Dabrafenib—SLC22A8—brain—Alzheimer's disease	0.000935	0.00791	CbGeAlD
Dabrafenib—Mental disorder—Donepezil—Alzheimer's disease	0.000935	0.00228	CcSEcCtD
Dabrafenib—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.000933	0.00228	CcSEcCtD
Dabrafenib—Connective tissue disorder—Rivastigmine—Alzheimer's disease	0.000931	0.00228	CcSEcCtD
Dabrafenib—Urethral disorder—Rivastigmine—Alzheimer's disease	0.000929	0.00227	CcSEcCtD
Dabrafenib—Erythema—Donepezil—Alzheimer's disease	0.000929	0.00227	CcSEcCtD
Dabrafenib—Malnutrition—Donepezil—Alzheimer's disease	0.000929	0.00227	CcSEcCtD
Dabrafenib—Hypotension—Galantamine—Alzheimer's disease	0.000914	0.00223	CcSEcCtD
Dabrafenib—Eye disorder—Memantine—Alzheimer's disease	0.000905	0.00221	CcSEcCtD
Dabrafenib—Back pain—Donepezil—Alzheimer's disease	0.000898	0.0022	CcSEcCtD
Dabrafenib—ABCB1—embryo—Alzheimer's disease	0.000894	0.00756	CbGeAlD
Dabrafenib—Muscle spasms—Donepezil—Alzheimer's disease	0.000893	0.00218	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000891	0.00218	CcSEcCtD
Dabrafenib—Eye disorder—Rivastigmine—Alzheimer's disease	0.000885	0.00216	CcSEcCtD
Dabrafenib—Insomnia—Galantamine—Alzheimer's disease	0.000884	0.00216	CcSEcCtD
Dabrafenib—Angiopathy—Memantine—Alzheimer's disease	0.000879	0.00215	CcSEcCtD
Dabrafenib—Vision blurred—Donepezil—Alzheimer's disease	0.000875	0.00214	CcSEcCtD
Dabrafenib—Immune system disorder—Memantine—Alzheimer's disease	0.000875	0.00214	CcSEcCtD
Dabrafenib—Mediastinal disorder—Memantine—Alzheimer's disease	0.000873	0.00213	CcSEcCtD
Dabrafenib—Chills—Memantine—Alzheimer's disease	0.000869	0.00212	CcSEcCtD
Dabrafenib—Arrhythmia—Memantine—Alzheimer's disease	0.000865	0.00211	CcSEcCtD
Dabrafenib—Angiopathy—Rivastigmine—Alzheimer's disease	0.00086	0.0021	CcSEcCtD
Dabrafenib—Anaemia—Donepezil—Alzheimer's disease	0.000858	0.0021	CcSEcCtD
Dabrafenib—Alopecia—Memantine—Alzheimer's disease	0.000856	0.00209	CcSEcCtD
Dabrafenib—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000854	0.00209	CcSEcCtD
Dabrafenib—Chills—Rivastigmine—Alzheimer's disease	0.00085	0.00208	CcSEcCtD
Dabrafenib—Decreased appetite—Galantamine—Alzheimer's disease	0.00085	0.00208	CcSEcCtD
Dabrafenib—Mental disorder—Memantine—Alzheimer's disease	0.000849	0.00207	CcSEcCtD
Dabrafenib—Arrhythmia—Rivastigmine—Alzheimer's disease	0.000846	0.00207	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000844	0.00206	CcSEcCtD
Dabrafenib—Malnutrition—Memantine—Alzheimer's disease	0.000843	0.00206	CcSEcCtD
Dabrafenib—Fatigue—Galantamine—Alzheimer's disease	0.000843	0.00206	CcSEcCtD
Dabrafenib—Alopecia—Rivastigmine—Alzheimer's disease	0.000837	0.00205	CcSEcCtD
Dabrafenib—Constipation—Galantamine—Alzheimer's disease	0.000836	0.00204	CcSEcCtD
Dabrafenib—Mental disorder—Rivastigmine—Alzheimer's disease	0.00083	0.00203	CcSEcCtD
Dabrafenib—Malnutrition—Rivastigmine—Alzheimer's disease	0.000825	0.00202	CcSEcCtD
Dabrafenib—Erythema—Rivastigmine—Alzheimer's disease	0.000825	0.00202	CcSEcCtD
Dabrafenib—ABCG2—cerebellum—Alzheimer's disease	0.000819	0.00693	CbGeAlD
Dabrafenib—Back pain—Memantine—Alzheimer's disease	0.000816	0.00199	CcSEcCtD
Dabrafenib—Cough—Donepezil—Alzheimer's disease	0.00081	0.00198	CcSEcCtD
Dabrafenib—Hypertension—Donepezil—Alzheimer's disease	0.000802	0.00196	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.0008	0.00195	CcSEcCtD
Dabrafenib—Back pain—Rivastigmine—Alzheimer's disease	0.000798	0.00195	CcSEcCtD
Dabrafenib—Vision blurred—Memantine—Alzheimer's disease	0.000795	0.00194	CcSEcCtD
Dabrafenib—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000793	0.00194	CcSEcCtD
Dabrafenib—Arthralgia—Donepezil—Alzheimer's disease	0.000791	0.00193	CcSEcCtD
Dabrafenib—Myalgia—Donepezil—Alzheimer's disease	0.000791	0.00193	CcSEcCtD
Dabrafenib—ABCB1—forebrain—Alzheimer's disease	0.00079	0.00669	CbGeAlD
Dabrafenib—Anaemia—Memantine—Alzheimer's disease	0.000779	0.0019	CcSEcCtD
Dabrafenib—Vision blurred—Rivastigmine—Alzheimer's disease	0.000777	0.0019	CcSEcCtD
Dabrafenib—Dry mouth—Donepezil—Alzheimer's disease	0.000773	0.00189	CcSEcCtD
Dabrafenib—Body temperature increased—Galantamine—Alzheimer's disease	0.000773	0.00189	CcSEcCtD
Dabrafenib—Abdominal pain—Galantamine—Alzheimer's disease	0.000773	0.00189	CcSEcCtD
Dabrafenib—Anaemia—Rivastigmine—Alzheimer's disease	0.000762	0.00186	CcSEcCtD
Dabrafenib—Oedema—Donepezil—Alzheimer's disease	0.000758	0.00185	CcSEcCtD
Dabrafenib—Leukopenia—Memantine—Alzheimer's disease	0.000755	0.00184	CcSEcCtD
Dabrafenib—Infection—Donepezil—Alzheimer's disease	0.000753	0.00184	CcSEcCtD
Dabrafenib—Nervous system disorder—Donepezil—Alzheimer's disease	0.000743	0.00182	CcSEcCtD
Dabrafenib—Thrombocytopenia—Donepezil—Alzheimer's disease	0.000742	0.00181	CcSEcCtD
Dabrafenib—Cough—Memantine—Alzheimer's disease	0.000736	0.0018	CcSEcCtD
Dabrafenib—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000733	0.00179	CcSEcCtD
Dabrafenib—Hypertension—Memantine—Alzheimer's disease	0.000728	0.00178	CcSEcCtD
Dabrafenib—ABCB1—telencephalon—Alzheimer's disease	0.000727	0.00615	CbGeAlD
Dabrafenib—Hypersensitivity—Galantamine—Alzheimer's disease	0.00072	0.00176	CcSEcCtD
Dabrafenib—Cough—Rivastigmine—Alzheimer's disease	0.00072	0.00176	CcSEcCtD
Dabrafenib—Myalgia—Memantine—Alzheimer's disease	0.000718	0.00175	CcSEcCtD
Dabrafenib—Arthralgia—Memantine—Alzheimer's disease	0.000718	0.00175	CcSEcCtD
Dabrafenib—Hypertension—Rivastigmine—Alzheimer's disease	0.000712	0.00174	CcSEcCtD
Dabrafenib—Hypotension—Donepezil—Alzheimer's disease	0.000708	0.00173	CcSEcCtD
Dabrafenib—Myalgia—Rivastigmine—Alzheimer's disease	0.000702	0.00172	CcSEcCtD
Dabrafenib—Arthralgia—Rivastigmine—Alzheimer's disease	0.000702	0.00172	CcSEcCtD
Dabrafenib—Dry mouth—Memantine—Alzheimer's disease	0.000702	0.00172	CcSEcCtD
Dabrafenib—Asthenia—Galantamine—Alzheimer's disease	0.000702	0.00171	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000697	0.0017	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.00069	0.00169	CcSEcCtD
Dabrafenib—Oedema—Memantine—Alzheimer's disease	0.000688	0.00168	CcSEcCtD
Dabrafenib—Dry mouth—Rivastigmine—Alzheimer's disease	0.000687	0.00168	CcSEcCtD
Dabrafenib—Insomnia—Donepezil—Alzheimer's disease	0.000685	0.00168	CcSEcCtD
Dabrafenib—CYP2C8—brain—Alzheimer's disease	0.000684	0.00579	CbGeAlD
Dabrafenib—Infection—Memantine—Alzheimer's disease	0.000684	0.00167	CcSEcCtD
Dabrafenib—Nervous system disorder—Memantine—Alzheimer's disease	0.000675	0.00165	CcSEcCtD
Dabrafenib—Thrombocytopenia—Memantine—Alzheimer's disease	0.000674	0.00165	CcSEcCtD
Dabrafenib—Oedema—Rivastigmine—Alzheimer's disease	0.000673	0.00165	CcSEcCtD
Dabrafenib—Diarrhoea—Galantamine—Alzheimer's disease	0.000669	0.00164	CcSEcCtD
Dabrafenib—Infection—Rivastigmine—Alzheimer's disease	0.000669	0.00163	CcSEcCtD
Dabrafenib—Skin disorder—Memantine—Alzheimer's disease	0.000668	0.00163	CcSEcCtD
Dabrafenib—Hyperhidrosis—Memantine—Alzheimer's disease	0.000665	0.00163	CcSEcCtD
Dabrafenib—ABCG2—brain—Alzheimer's disease	0.000665	0.00563	CbGeAlD
Dabrafenib—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.00066	0.00161	CcSEcCtD
Dabrafenib—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.000659	0.00161	CcSEcCtD
Dabrafenib—Decreased appetite—Donepezil—Alzheimer's disease	0.000659	0.00161	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000654	0.0016	CcSEcCtD
Dabrafenib—Skin disorder—Rivastigmine—Alzheimer's disease	0.000654	0.0016	CcSEcCtD
Dabrafenib—Fatigue—Donepezil—Alzheimer's disease	0.000653	0.0016	CcSEcCtD
Dabrafenib—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.000651	0.00159	CcSEcCtD
Dabrafenib—Constipation—Donepezil—Alzheimer's disease	0.000648	0.00158	CcSEcCtD
Dabrafenib—Dizziness—Galantamine—Alzheimer's disease	0.000647	0.00158	CcSEcCtD
Dabrafenib—Hypotension—Memantine—Alzheimer's disease	0.000643	0.00157	CcSEcCtD
Dabrafenib—Hypotension—Rivastigmine—Alzheimer's disease	0.000629	0.00154	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000627	0.00153	CcSEcCtD
Dabrafenib—Insomnia—Memantine—Alzheimer's disease	0.000622	0.00152	CcSEcCtD
Dabrafenib—Vomiting—Galantamine—Alzheimer's disease	0.000622	0.00152	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.00062	0.00151	CcSEcCtD
Dabrafenib—Rash—Galantamine—Alzheimer's disease	0.000617	0.00151	CcSEcCtD
Dabrafenib—Dermatitis—Galantamine—Alzheimer's disease	0.000616	0.00151	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.000613	0.0015	CcSEcCtD
Dabrafenib—Headache—Galantamine—Alzheimer's disease	0.000613	0.0015	CcSEcCtD
Dabrafenib—Insomnia—Rivastigmine—Alzheimer's disease	0.000609	0.00149	CcSEcCtD
Dabrafenib—CYP3A4—nervous system—Alzheimer's disease	0.000606	0.00513	CbGeAlD
Dabrafenib—Abdominal pain—Donepezil—Alzheimer's disease	0.000599	0.00146	CcSEcCtD
Dabrafenib—Body temperature increased—Donepezil—Alzheimer's disease	0.000599	0.00146	CcSEcCtD
Dabrafenib—Decreased appetite—Memantine—Alzheimer's disease	0.000598	0.00146	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000594	0.00145	CcSEcCtD
Dabrafenib—Fatigue—Memantine—Alzheimer's disease	0.000593	0.00145	CcSEcCtD
Dabrafenib—Constipation—Memantine—Alzheimer's disease	0.000588	0.00144	CcSEcCtD
Dabrafenib—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000585	0.00143	CcSEcCtD
Dabrafenib—CYP3A4—central nervous system—Alzheimer's disease	0.000584	0.00494	CbGeAlD
Dabrafenib—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000581	0.00142	CcSEcCtD
Dabrafenib—Nausea—Galantamine—Alzheimer's disease	0.000581	0.00142	CcSEcCtD
Dabrafenib—Fatigue—Rivastigmine—Alzheimer's disease	0.00058	0.00142	CcSEcCtD
Dabrafenib—Constipation—Rivastigmine—Alzheimer's disease	0.000576	0.00141	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000563	0.00138	CcSEcCtD
Dabrafenib—Hypersensitivity—Donepezil—Alzheimer's disease	0.000558	0.00136	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.00055	0.00135	CcSEcCtD
Dabrafenib—Abdominal pain—Memantine—Alzheimer's disease	0.000544	0.00133	CcSEcCtD
Dabrafenib—Body temperature increased—Memantine—Alzheimer's disease	0.000544	0.00133	CcSEcCtD
Dabrafenib—Asthenia—Donepezil—Alzheimer's disease	0.000544	0.00133	CcSEcCtD
Dabrafenib—Pruritus—Donepezil—Alzheimer's disease	0.000536	0.00131	CcSEcCtD
Dabrafenib—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000532	0.0013	CcSEcCtD
Dabrafenib—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000532	0.0013	CcSEcCtD
Dabrafenib—Diarrhoea—Donepezil—Alzheimer's disease	0.000519	0.00127	CcSEcCtD
Dabrafenib—Hypersensitivity—Memantine—Alzheimer's disease	0.000507	0.00124	CcSEcCtD
Dabrafenib—Dizziness—Donepezil—Alzheimer's disease	0.000501	0.00122	CcSEcCtD
Dabrafenib—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.000496	0.00121	CcSEcCtD
Dabrafenib—Asthenia—Memantine—Alzheimer's disease	0.000494	0.00121	CcSEcCtD
Dabrafenib—Pruritus—Memantine—Alzheimer's disease	0.000487	0.00119	CcSEcCtD
Dabrafenib—Asthenia—Rivastigmine—Alzheimer's disease	0.000483	0.00118	CcSEcCtD
Dabrafenib—Vomiting—Donepezil—Alzheimer's disease	0.000482	0.00118	CcSEcCtD
Dabrafenib—Rash—Donepezil—Alzheimer's disease	0.000478	0.00117	CcSEcCtD
Dabrafenib—Dermatitis—Donepezil—Alzheimer's disease	0.000477	0.00117	CcSEcCtD
Dabrafenib—Pruritus—Rivastigmine—Alzheimer's disease	0.000476	0.00116	CcSEcCtD
Dabrafenib—Headache—Donepezil—Alzheimer's disease	0.000475	0.00116	CcSEcCtD
Dabrafenib—Diarrhoea—Memantine—Alzheimer's disease	0.000471	0.00115	CcSEcCtD
Dabrafenib—Diarrhoea—Rivastigmine—Alzheimer's disease	0.000461	0.00113	CcSEcCtD
Dabrafenib—Dizziness—Memantine—Alzheimer's disease	0.000455	0.00111	CcSEcCtD
Dabrafenib—Nausea—Donepezil—Alzheimer's disease	0.00045	0.0011	CcSEcCtD
Dabrafenib—Dizziness—Rivastigmine—Alzheimer's disease	0.000445	0.00109	CcSEcCtD
Dabrafenib—Vomiting—Memantine—Alzheimer's disease	0.000437	0.00107	CcSEcCtD
Dabrafenib—Rash—Memantine—Alzheimer's disease	0.000434	0.00106	CcSEcCtD
Dabrafenib—Dermatitis—Memantine—Alzheimer's disease	0.000433	0.00106	CcSEcCtD
Dabrafenib—Headache—Memantine—Alzheimer's disease	0.000431	0.00105	CcSEcCtD
Dabrafenib—ABCB1—nervous system—Alzheimer's disease	0.000429	0.00363	CbGeAlD
Dabrafenib—Vomiting—Rivastigmine—Alzheimer's disease	0.000428	0.00105	CcSEcCtD
Dabrafenib—Rash—Rivastigmine—Alzheimer's disease	0.000424	0.00104	CcSEcCtD
Dabrafenib—Dermatitis—Rivastigmine—Alzheimer's disease	0.000424	0.00104	CcSEcCtD
Dabrafenib—Headache—Rivastigmine—Alzheimer's disease	0.000422	0.00103	CcSEcCtD
Dabrafenib—ABCB1—central nervous system—Alzheimer's disease	0.000413	0.0035	CbGeAlD
Dabrafenib—Nausea—Memantine—Alzheimer's disease	0.000409	0.000999	CcSEcCtD
Dabrafenib—ABCB1—cerebellum—Alzheimer's disease	0.000404	0.00342	CbGeAlD
Dabrafenib—Nausea—Rivastigmine—Alzheimer's disease	0.0004	0.000977	CcSEcCtD
Dabrafenib—ABCB1—brain—Alzheimer's disease	0.000328	0.00278	CbGeAlD
Dabrafenib—SLCO1B1—Metabolism—PLCB1—Alzheimer's disease	2.38e-05	7.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—INS—Alzheimer's disease	2.37e-05	7.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTK2B—Alzheimer's disease	2.36e-05	7.15e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA4—Alzheimer's disease	2.36e-05	7.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—Alzheimer's disease	2.34e-05	7.09e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—LPL—Alzheimer's disease	2.33e-05	7.07e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—BCHE—Alzheimer's disease	2.33e-05	7.07e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	2.33e-05	7.07e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—LPL—Alzheimer's disease	2.32e-05	7.03e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ABCA1—Alzheimer's disease	2.31e-05	6.98e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MEF2C—Alzheimer's disease	2.3e-05	6.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SST—Alzheimer's disease	2.3e-05	6.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GAB2—Alzheimer's disease	2.3e-05	6.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NTRK2—Alzheimer's disease	2.3e-05	6.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—LPL—Alzheimer's disease	2.29e-05	6.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CALM1—Alzheimer's disease	2.29e-05	6.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GSK3A—Alzheimer's disease	2.28e-05	6.89e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CALM1—Alzheimer's disease	2.26e-05	6.86e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—APOE—Alzheimer's disease	2.26e-05	6.84e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PRKCG—Alzheimer's disease	2.26e-05	6.84e-05	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—Alzheimer's disease	2.25e-05	6.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APP—Alzheimer's disease	2.24e-05	6.78e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CAV1—Alzheimer's disease	2.24e-05	6.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PRKCG—Alzheimer's disease	2.23e-05	6.75e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GAPDHS—Alzheimer's disease	2.22e-05	6.71e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—Alzheimer's disease	2.2e-05	6.67e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PLCB1—Alzheimer's disease	2.2e-05	6.67e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NGF—Alzheimer's disease	2.2e-05	6.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—Alzheimer's disease	2.18e-05	6.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—AKT1—Alzheimer's disease	2.16e-05	6.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—F2—Alzheimer's disease	2.15e-05	6.51e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CHAT—Alzheimer's disease	2.14e-05	6.5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TPI1—Alzheimer's disease	2.14e-05	6.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—Alzheimer's disease	2.14e-05	6.49e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR5—Alzheimer's disease	2.14e-05	6.48e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ABCA1—Alzheimer's disease	2.13e-05	6.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—Alzheimer's disease	2.12e-05	6.41e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—HMOX1—Alzheimer's disease	2.11e-05	6.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCR5—Alzheimer's disease	2.11e-05	6.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PLCB1—Alzheimer's disease	2.11e-05	6.4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ATP5A1—Alzheimer's disease	2.1e-05	6.36e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR2A—Alzheimer's disease	2.09e-05	6.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK8—Alzheimer's disease	2.09e-05	6.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CALM1—Alzheimer's disease	2.09e-05	6.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS3—Alzheimer's disease	2.08e-05	6.3e-05	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—AKT1—Alzheimer's disease	2.07e-05	6.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—Alzheimer's disease	2.06e-05	6.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MAOB—Alzheimer's disease	2.06e-05	6.23e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—Alzheimer's disease	2.02e-05	6.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—Alzheimer's disease	2e-05	6.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLD3—Alzheimer's disease	2e-05	6.07e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARGC1A—Alzheimer's disease	1.99e-05	6.02e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GAPDH—Alzheimer's disease	1.98e-05	5.99e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HMOX1—Alzheimer's disease	1.98e-05	5.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NGFR—Alzheimer's disease	1.97e-05	5.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—Alzheimer's disease	1.97e-05	5.96e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PPARG—Alzheimer's disease	1.97e-05	5.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CREB1—Alzheimer's disease	1.96e-05	5.93e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	1.96e-05	5.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CALM1—Alzheimer's disease	1.95e-05	5.91e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APOE—Alzheimer's disease	1.95e-05	5.89e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—LEP—Alzheimer's disease	1.95e-05	5.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	1.94e-05	5.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CALM1—Alzheimer's disease	1.93e-05	5.84e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—INS—Alzheimer's disease	1.93e-05	5.84e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CAV1—Alzheimer's disease	1.93e-05	5.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADAM10—Alzheimer's disease	1.92e-05	5.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOE—Alzheimer's disease	1.92e-05	5.82e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSD17B10—Alzheimer's disease	1.92e-05	5.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL2—Alzheimer's disease	1.91e-05	5.8e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—A2M—Alzheimer's disease	1.91e-05	5.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CAV1—Alzheimer's disease	1.9e-05	5.77e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—Alzheimer's disease	1.9e-05	5.77e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Alzheimer's disease	1.89e-05	5.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—Alzheimer's disease	1.87e-05	5.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CHAT—Alzheimer's disease	1.87e-05	5.66e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TPI1—Alzheimer's disease	1.87e-05	5.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ESR1—Alzheimer's disease	1.86e-05	5.63e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP46A1—Alzheimer's disease	1.85e-05	5.6e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARGC1A—Alzheimer's disease	1.84e-05	5.57e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—F2—Alzheimer's disease	1.83e-05	5.56e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HMOX1—Alzheimer's disease	1.83e-05	5.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—S100B—Alzheimer's disease	1.82e-05	5.51e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—LPL—Alzheimer's disease	1.81e-05	5.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—GSK3B—Alzheimer's disease	1.8e-05	5.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOTCH1—Alzheimer's disease	1.8e-05	5.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—Alzheimer's disease	1.79e-05	5.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MAOB—Alzheimer's disease	1.79e-05	5.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CREB1—Alzheimer's disease	1.79e-05	5.42e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ND1—Alzheimer's disease	1.79e-05	5.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOTCH1—Alzheimer's disease	1.77e-05	5.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF2—Alzheimer's disease	1.73e-05	5.25e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GAPDH—Alzheimer's disease	1.72e-05	5.22e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	1.7e-05	5.16e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NOS3—Alzheimer's disease	1.69e-05	5.12e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GSK3B—Alzheimer's disease	1.68e-05	5.1e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—LPL—Alzheimer's disease	1.67e-05	5.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1R—Alzheimer's disease	1.67e-05	5.07e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CREB1—Alzheimer's disease	1.67e-05	5.06e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—A2M—Alzheimer's disease	1.66e-05	5.04e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—Alzheimer's disease	1.66e-05	5.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—GSK3B—Alzheimer's disease	1.66e-05	5.04e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ACHE—Alzheimer's disease	1.66e-05	5.04e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—INS—Alzheimer's disease	1.66e-05	5.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CREB1—Alzheimer's disease	1.65e-05	5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—INPP5D—Alzheimer's disease	1.64e-05	4.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—INS—Alzheimer's disease	1.64e-05	4.97e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL2—Alzheimer's disease	1.64e-05	4.95e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—Alzheimer's disease	1.63e-05	4.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—Alzheimer's disease	1.62e-05	4.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1—Alzheimer's disease	1.61e-05	4.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LPL—Alzheimer's disease	1.61e-05	4.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MEF2C—Alzheimer's disease	1.59e-05	4.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKCG—Alzheimer's disease	1.56e-05	4.73e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS1—Alzheimer's disease	1.56e-05	4.72e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO1—Alzheimer's disease	1.56e-05	4.72e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—Alzheimer's disease	1.55e-05	4.68e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2D6—Alzheimer's disease	1.53e-05	4.63e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CALM1—Alzheimer's disease	1.52e-05	4.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NGF—Alzheimer's disease	1.52e-05	4.61e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—Alzheimer's disease	1.52e-05	4.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—Alzheimer's disease	1.51e-05	4.58e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—Alzheimer's disease	1.51e-05	4.57e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CAV1—Alzheimer's disease	1.5e-05	4.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL2—Alzheimer's disease	1.5e-05	4.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—Alzheimer's disease	1.48e-05	4.48e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—Alzheimer's disease	1.46e-05	4.41e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ACHE—Alzheimer's disease	1.45e-05	4.39e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—BCHE—Alzheimer's disease	1.45e-05	4.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR2A—Alzheimer's disease	1.45e-05	4.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—Alzheimer's disease	1.44e-05	4.36e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—INPP5D—Alzheimer's disease	1.43e-05	4.34e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CALM1—Alzheimer's disease	1.41e-05	4.27e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—Alzheimer's disease	1.41e-05	4.26e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—Alzheimer's disease	1.4e-05	4.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—Alzheimer's disease	1.39e-05	4.22e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CAV1—Alzheimer's disease	1.39e-05	4.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—Alzheimer's disease	1.38e-05	4.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—Alzheimer's disease	1.37e-05	4.14e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLCB1—Alzheimer's disease	1.37e-05	4.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS1—Alzheimer's disease	1.36e-05	4.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO1—Alzheimer's disease	1.36e-05	4.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CALM1—Alzheimer's disease	1.35e-05	4.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—Alzheimer's disease	1.35e-05	4.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LEP—Alzheimer's disease	1.35e-05	4.08e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	1.34e-05	4.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—Alzheimer's disease	1.33e-05	4.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CAV1—Alzheimer's disease	1.33e-05	4.04e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2D6—Alzheimer's disease	1.33e-05	4.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—Alzheimer's disease	1.33e-05	4.02e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCA1—Alzheimer's disease	1.32e-05	4.01e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—Alzheimer's disease	1.32e-05	4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—Alzheimer's disease	1.32e-05	3.99e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—INS—Alzheimer's disease	1.3e-05	3.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—Alzheimer's disease	1.28e-05	3.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—F2—Alzheimer's disease	1.27e-05	3.84e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BCHE—Alzheimer's disease	1.26e-05	3.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH1—Alzheimer's disease	1.24e-05	3.76e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—Alzheimer's disease	1.24e-05	3.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—Alzheimer's disease	1.23e-05	3.73e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—Alzheimer's disease	1.22e-05	3.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK8—Alzheimer's disease	1.22e-05	3.69e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—INS—Alzheimer's disease	1.2e-05	3.63e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLCB1—Alzheimer's disease	1.19e-05	3.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—Alzheimer's disease	1.18e-05	3.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GSK3B—Alzheimer's disease	1.17e-05	3.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CREB1—Alzheimer's disease	1.16e-05	3.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ABCA1—Alzheimer's disease	1.15e-05	3.5e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TPI1—Alzheimer's disease	1.15e-05	3.49e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CHAT—Alzheimer's disease	1.15e-05	3.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—INS—Alzheimer's disease	1.15e-05	3.48e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARGC1A—Alzheimer's disease	1.14e-05	3.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK8—Alzheimer's disease	1.14e-05	3.44e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—Alzheimer's disease	1.14e-05	3.44e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—Alzheimer's disease	1.14e-05	3.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—Alzheimer's disease	1.13e-05	3.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—Alzheimer's disease	1.11e-05	3.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MAOB—Alzheimer's disease	1.1e-05	3.34e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	1.06e-05	3.22e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—Alzheimer's disease	1.05e-05	3.19e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—Alzheimer's disease	1.05e-05	3.18e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LPL—Alzheimer's disease	1.04e-05	3.15e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—Alzheimer's disease	1.04e-05	3.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—Alzheimer's disease	1.04e-05	3.14e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—A2M—Alzheimer's disease	1.03e-05	3.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—Alzheimer's disease	1.01e-05	3.05e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARGC1A—Alzheimer's disease	9.95e-06	3.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—Alzheimer's disease	9.9e-06	3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—Alzheimer's disease	9.64e-06	2.92e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—Alzheimer's disease	9.62e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—Alzheimer's disease	9.57e-06	2.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—Alzheimer's disease	9.52e-06	2.88e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—Alzheimer's disease	9.36e-06	2.84e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LPL—Alzheimer's disease	9.05e-06	2.74e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACHE—Alzheimer's disease	8.92e-06	2.7e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	8.82e-06	2.67e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CALM1—Alzheimer's disease	8.74e-06	2.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—Alzheimer's disease	8.71e-06	2.64e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAV1—Alzheimer's disease	8.63e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—Alzheimer's disease	8.56e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—Alzheimer's disease	8.5e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	8.36e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO1—Alzheimer's disease	8.36e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	8.2e-06	2.48e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—Alzheimer's disease	8.15e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—Alzheimer's disease	7.93e-06	2.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK8—Alzheimer's disease	7.87e-06	2.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—Alzheimer's disease	7.85e-06	2.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BCHE—Alzheimer's disease	7.77e-06	2.35e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—Alzheimer's disease	7.77e-06	2.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—Alzheimer's disease	7.77e-06	2.35e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CALM1—Alzheimer's disease	7.62e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—Alzheimer's disease	7.59e-06	2.3e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—Alzheimer's disease	7.59e-06	2.3e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAV1—Alzheimer's disease	7.52e-06	2.28e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—INS—Alzheimer's disease	7.44e-06	2.25e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	7.33e-06	2.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—Alzheimer's disease	7.26e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—Alzheimer's disease	7.26e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—Alzheimer's disease	7.17e-06	2.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—Alzheimer's disease	7.17e-06	2.17e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	7.11e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—Alzheimer's disease	6.7e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—Alzheimer's disease	6.67e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—Alzheimer's disease	6.62e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—Alzheimer's disease	6.61e-06	2e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—Alzheimer's disease	6.53e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—INS—Alzheimer's disease	6.48e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	6.13e-06	1.86e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	6.1e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—Alzheimer's disease	5.97e-06	1.81e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—Alzheimer's disease	5.69e-06	1.72e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPL—Alzheimer's disease	5.58e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—Alzheimer's disease	5.49e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—Alzheimer's disease	5.22e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—Alzheimer's disease	5.2e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—Alzheimer's disease	5.02e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	5.02e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—Alzheimer's disease	4.83e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CALM1—Alzheimer's disease	4.69e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—Alzheimer's disease	4.68e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—Alzheimer's disease	4.63e-06	1.4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAV1—Alzheimer's disease	4.63e-06	1.4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—Alzheimer's disease	4.07e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—INS—Alzheimer's disease	3.99e-06	1.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—Alzheimer's disease	3.5e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	3.2e-06	9.71e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—Alzheimer's disease	3e-06	9.09e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—Alzheimer's disease	2.61e-06	7.92e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—Alzheimer's disease	1.61e-06	4.88e-06	CbGpPWpGaD
